Pcsk 9 Sirna denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for pcsk9 sirna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied This Claim — and Why You Can Appeal

Cigna's "not FDA-approved" denial for a PCSK9 siRNA therapy typically means one of two things: the specific product your prescriber ordered has not yet received FDA clearance for the indication in your diagnosis, or Cigna's internal formulary policy treats the product as investigational despite regulatory status. PCSK9 therapies represent a rapidly evolving class, and approval timelines and labeled indications differ across individual agents in the class. Verify the exact FDA approval status and labeled indication for the specific product prescribed by checking the current FDA label directly.

## Your Federal Appeal Rights

You have layered federal protections:

• Internal appeal (ERISA §503 / ACA §2719): You must first exhaust your plan's internal process. Submit a written internal appeal within the timeframe stated on your denial notice (typically 180 days from receipt).
• External review: After a final internal denial, you may escalate to an independent external review organization (IRO). Under ACA §2719, most non-grandfathered plans must offer external review. You generally have approximately four months from the final internal denial to file.
• Expedited review: If the standard timeline would seriously jeopardize your health, request an expedited internal and expedited external review simultaneously. Expedited decisions are typically required within 72 hours.

## Documentation to Gather

Assemble the following before filing:

1. Diagnosis confirmation — chart notes, lab reports, imaging, and any specialist evaluation confirming your diagnosis and clinical severity. 2. Prior-treatment history — dated records for every prior lipid-lowering or cardiovascular medication tried, including duration, doses (from chart), and documented reasons for discontinuation or inadequate response. 3. Current medication list and clinical context — a current problem list and any comorbidities relevant to cardiovascular risk. 4. Prescriber's medical-necessity letter — a detailed letter from your cardiologist or treating physician explaining why this specific agent is necessary for your individual case, referencing the applicable guideline organization (e.g., the ACC/AHA guideline on cholesterol management) and your documented clinical history. 5. FDA prescribing label — attach the current approved label showing the indication under which the drug is prescribed.

## Criteria-Mapping Structure for Your Appeal Letter

Organize your appeal argument as a point-by-point response to Cigna's denial rationale:

| Cigna's stated reason | Your chart-based response | |---|---| | Product not FDA-approved for this indication | Quote the exact labeled indication from the FDA prescribing information; confirm your diagnosis matches | | Policy treats product as investigational | Cite the approval date and reference that Cigna's own medical policy should reflect current FDA status |

Close the letter by requesting that Cigna provide the precise policy provision used to deny, the specific clinical criteria your case allegedly fails to meet, and the name and credentials of the reviewer. This forces a more specific, reviewable denial if upheld.